Acute Coronary Syndrome

Type: Keyphrase

Name: Acute Coronary Syndrome

First reported 10 hours ago - Updated 10 hours ago - 1 reports

ESC Congress 2013: What’s in it for the Media?

The world's greatest event in cardiology, ESC Congress 2013, will take place in Amsterdam, the Netherlands, from 31 August to 4 September, and as ever promises journalists a rich source of front-page news and feature background.The spotlight of this year's ... [Published European Society of Cardiology - 10 hours ago]

Entities: Acute Coronary Syndrome, Amsterdam, Alogliptin, Clinical trials

First reported 21 hours ago - Updated 15 hours ago - 1 reports

Daiichi Sankyo Co Ltd

DAIICHI SANKYO COMPANY, LIMITED: Daiichi Sankyo Submits a New Drug Application in Japan for the Antiplatelet Agent Prasugrel

Company name: DAIICHI SANKYO COMPANY, LIMITEDRepresentative: Joji Nakayama, President and CEO(Code no.: 4568, First Section of Tokyo and Osaka Stock Exchanges)Please address inquiries to Noriaki Ishida, Corporate Officer,Vice President, Corporate Communications ... [Published 4 Traders - 21 hours ago]

Entities: Prasugrel, Daiichi Sankyo Co Ltd, Percutaneous Coronary Intervention

First reported Jun 17 2013 - Updated Jun 17 2013 - 1 reports

Index Ventures taps Big Pharma-backed fund to hatch anticoagulant upstart

With an experimental therapy that could save "millions of lives," biotech startup XO1 Ltd. said it has raised $11 million in a Series A round of financing from Index Ventures. Index Ventures has formed the startup and invested in the young company from ... [Published FierceBiotech - Jun 17 2013]

Entities: Anticoagulant, XO1 Ltd, Index Ventures, Antibody

First reported Jun 16 2013 - Updated Jun 16 2013 - 1 reports

University of Melbourne

Heart attack danger comes back to haunt

THE number of Australians who die from repeat heart attacks is expected to almost double by 2020. Experts say a medical system failing to adequately track the progress of survivors is to blame.Australia's leading cardiologists gathered at the Acute Coronary ... [Published Adelaide Now - Jun 16 2013]

Entities: Heart Attack, Patient, myocarditis, Acute Coronary Syndrome, University of Melbourne

First reported Jun 14 2013 - Updated Jun 14 2013 - 1 reports

215 cardiovascular drugs under development

The drug development pipeline for cardiovascular medicines runneth over, according to a report by PhRMA. Still, that may translate into only a few new products.Pharmaceutical Research and Manufacturers of America (PhRMA), a company that represents biopharmaceutical ... [Published Cardiovascular Business - Jun 14 2013]

Entities: Drugs, congestive heart failure, Biopharmaceuticals

First reported Jun 14 2013 - Updated Jun 14 2013 - 1 reports

Study Data from Minneapolis Heart Institute Foundation Update Knowledge of Heart Failure

(NewsRx) -- By a News Reporter-Staff News Editor at Heart Disease Weekly -- Investigators publish new report on Heart Failure. According to news originating from Minneapolis, Minnesota, by NewsRx editors, the research stated, "Takotsubo Cardiomyopathy: ... [Published NewsRX - Jun 14 2013]

Entities: Minneapolis Heart Institute, Cardiomyopathy, Acute Coronary Syndrome

First reported Jun 13 2013 - Updated Jun 13 2013 - 1 reports

ATLAS ACS-TIMI 51 and Missing Data

Rivaroxaban is a Factor Xa inhibitor that was recently reviewed by the Food and Drug Administration as a potential therapy to reduce the risk of recurrent atherothrombotic events in patients with acute coronary syndrome. Approval of this drug would represent ... [Published Journal of the American College of Cardiology - Jun 13 2013]

Entities: Rivaroxaban, Anticoagulant, Myocardial Infarction

First reported Jun 03 2013 - Updated Jun 04 2013 - 3 reports

Sanofi announces results of two Phase 3 clinical studies

Sanofi announced topline results of two Phase 3 clinical studies of its investigational compounds iniparib and otamixaban respectively. Sanofi announced topline results of two Phase 3 clinical studies of its investigational compounds iniparib and otamixaban ... [Published India Infoline - Jun 04 2013]

Entities: Iniparib, Otamixaban, Phase III, Sanofi SA

First reported May 30 2013 - Updated May 30 2013 - 2 reports

Visualizing Vulnerability Toward a New Cardiac Score *

Versteylen et al. 1 have made progress toward this personalization of risk assessment by following up 1,650 patients with stable chest pain who had undergone cardiac CTA for an average of 26 months and comparing the 26 patients who had an acute coronary ... [Published Journal of the American College of Cardiology - May 30 2013]

Entities: Vulnerability, Encumbrance, Patient, Multivariate analysis, Acute Coronary Syndrome

First reported May 24 2013 - Updated May 24 2013 - 3 reports

Bayer’s Xarelto® Approved in the EU for Secondary Prevention after an Acute Coronary Syndrome

Please confirm that you are a medical journalist.This website is intended to provide information to an international audience outside the USA and UK. Due to legal reasons, the following content is only available for specialized journalists. To access ... [Published Bayer HealthCare - May 24 2013]

Entities: Acute Coronary Syndrome, Xarelto, Bayer AG

First reported May 23 2013 - Updated May 24 2013 - 4 reports

New Market Report: MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - Current and Future Players

(live-PR.com) - Acute coronary syndrome (ACS) consists of two major diseases: myocardial infarction (MI) and unstable angina, with the former being one of the major killers in the mature markets. Though the incidence of ACS is either in decline or steady ... [Published Live-PR.com - May 24 2013]

Entities: Diagnostic, Biomarker, Acute Coronary Syndrome

First reported May 22 2013 - Updated May 23 2013 - 2 reports

MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes (Myocardial Infarction and Unstable Angina)- Current and Future Players

Research and Markets (http://www.researchandmarkets.com/research/mrdq2q/medipoint) has announced the addition of the "MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - Current and Future Players" report to their offering. MediPoint: ... [Published Individual.com - May 23 2013]

Entities: Acute Coronary Syndrome, Diagnostic, Myocardial Infarction, Biomarker

Quotes

"One of the interesting things about all the new oral anticoagulants that are in development or already on the market," Huntington says, "is that they are not being approved for [acute coronary syndrome] and part of the reason is they cause bleeding."

Index Ventures taps Big Pharma-backed fund to hatch anticoagulant upstart [Published FierceBiotech - Jun 17 2013]

...he had in the weeks that followed and was attributed to myocarditis - an inflammation of the heart doctors suspect was caused by a flu-like virus. "I was pretty fit and healthy in the first place and that's probably what saved my life" Mr McAndie, now 19, said

Heart attack danger comes back to haunt [Published Adelaide Now - Jun 16 2013]

...According to news reporting originating from Edinburgh, United Kingdom, by NewsRx correspondents, research stated, "We wished to determine the effect of an acute coronary syndrome (ACS) on putative endothelial progenitor cell (EPC) populations, and define their relationship to coronary artery disease (CAD) severity and clinical outcome, in order to clarify their clinical relevance. A prospective cohort study conducted in a tertiary referral cardiac centre."

Researchers from University of Edinburgh Report New Studies and Findings in the Area of Acute Cor ... [Published NewsRX - Jun 14 2013]

Our news journalists obtained a quote from the research from Minneapolis Heart Institute Foundation, "The author discusses key features that distinguish this cardiomyopathy from acute coronary syndrome. This review includes detail of characteristic findings... We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3."

Study Data from Minneapolis Heart Institute Foundation Update Knowledge of Heart Failure [Published NewsRX - Jun 14 2013]

More Content

sort by: Date \| Relevance
ESC Congress 2013: What’s in it for the Media? [Published European Society of Cardiology - 10 hours ago]
Hot Line Trials For European Society Of Cardiol... [Published Forbes.com - 13 hours ago]
Daiichi Sankyo submits a New Drug Application i... [Published European Pharmaceutical Review - 15 hours ago]
DAIICHI SANKYO COMPANY, LIMITED: Daiichi Sankyo... [Published 4 Traders - 21 hours ago]
Index Ventures backs novel anticoagulant [Published MedNous - Jun 17 2013]
Detailed guidance: Current medical guidelines: ... [Published Cabinet Office - Jun 17 2013]
Index Ventures taps Big Pharma-backed fund to h... [Published FierceBiotech - Jun 17 2013]
Heart attack danger comes back to haunt [Published Adelaide Now - Jun 16 2013]
England's Latest Innovation Scorecard: A Patchy... [Published Pharmaceutical Executive - Jun 15 2013]
215 cardiovascular drugs under development [Published Cardiovascular Business - Jun 14 2013]
Researchers from University of Edinburgh Report... [Published NewsRX - Jun 14 2013]
Study Data from Minneapolis Heart Institute Fou... [Published NewsRX - Jun 14 2013]
Researchers at Dalhousie University Report New ... [Published NewsRX - Jun 14 2013]
Aspirin administration by emergency medical dis... [Published Emergency Medicine Journal - Jun 14 2013]
CASS, AAPL, MDCO, EGO, SBAC, LINE Are Seasonall... [Published Individual.com - Jun 13 2013]
US biopharma: "215 heart disease/stroke drugs n... [Published Pharma Times - Jun 13 2013]
Release kinetics of circulating muscle-enriched... [Published Journal of the American College of Cardiology - Jun 13 2013]
ATLAS ACS-TIMI 51 and Missing Data [Published Journal of the American College of Cardiology - Jun 13 2013]
Sanofi's two Phase III cancer and ACS studies f... [Published Individual.com - Jun 12 2013]
Stress MRI Cuts Adverse Events Acute Chest Pain... [Published Physicians Practice - Jun 11 2013]
More doctors unclogging heart arteries through ... [Published FOXNews.com - Jun 11 2013]
Mechanisms of Acute Coronary Syndromes and Thei... [Published NEJM Most Emailed Articles - Jun 11 2013]
It’s rad: 1 in 6 PCIs in U.S. use radial approach [Published Cardiovascular Business - Jun 11 2013]
More doctors starting to favour 'wrist route' t... [Published Health24 - Jun 11 2013]
The Way to the Heart May Be the Wrist [Published Daily Rx - Jun 11 2013]
More Doctors Starting to Favor 'Wrist Route' to... [Published Health Finder - Jun 10 2013]
For PCI, Way to Heart Is Through the Wrist [Published MedPage Today - Jun 10 2013]
Unclogging heart arteries through wrist becomin... [Published Medical Xpress - Jun 10 2013]
US Interventional Cardiologists Dramatically In... [Published Forbes.com - Jun 10 2013]
"MediPoint: Diagnostic Cardiac Biomarkers for A... [Published SBWire - Jun 10 2013]

Blogs

sort by: Date \| Relevance
Mechanisms of Acute Coronary Syndromes and Thei... [Published NEJM Most Emailed Articles - Jun 11 2013]
Treating Acute Ischemic Stroke – The Race Is On [Published Brain Blogger - Jun 01 2013] As the fourth leading cause of death in the U.S. and a leading cause of permanent disability, stroke has an incredible impact at both the individual and economic level. According to the CDC, an American dies every 4 minutes as the result of an acute ...
Bayer’s Xarelto® Approved in the EU for Seconda... [Published Bayer Corporate News - May 24 2013] Following an ACS event, one in ten patients will have another major atherothrombotic event (cardiovascular death, myocardial infarction or stroke) within a year / Xarelto 2.5 mg BID in combination with antiplatelet therapy can help prevent athero-thrombotic ...
Cardiac surgery is not so bad [Published 3quarksdaily - Apr 01 2013] by Syed Tasnim Raza This is a response to the article " A Cardiac Conundrum " by Alice Park in the March-April 2013 issue of Harvard Magazine. The article mostly discusses a new book: Broken Hearts: The Tangled History of Cardiac Care by David ...
4 Healthcare Stock Stories for Tuesday Investme... [Published Wall St. Cheat Sheet - Mar 05 2013] Johnson & Johnson ( NYSE:JNJ ) Closing price $77.66 J&J’s Janssen Research & Development reports that the FDA has once again turned down the approval of its blood thinner Xarelto for patients suffering from a heart problem known as acute coronary ...

Press Releases

sort by: Date \| Relevance
Research and Markets: Global Acute Coronary Syn... [Published Business Wire - May 24 2013]
Research and Markets: Global Acute Coronary Syn... [Published Business Wire Health News - May 24 2013]
Research and Markets: MediPoint: Diagnostic Car... [Published Business Wire Health News - May 23 2013]
Research and Markets: MediPoint: Diagnostic Car... [Published Business Wire - May 22 2013]
Research and Markets: MediPoint: Diagnostic Car... [Published Business Wire Health News - May 22 2013]